A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Rexahn Pharmaceuticals, Inc.

ClinicalTrials.gov Identifier:

NCT01028495

First received: December 7, 2009

Last updated: August 28, 2012

Last verified: August 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2012
Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)